Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Master Service Agreement with ChemConnection BV, a Dutch contract manufacturing organization (CMO) to produce and supply clinical-grade MagSense® nanoparticle formulations for the Company’s planned HER2 breast cancer human clinical studies.
View the ASX announcement, “Imagion Biosystems Secures Nanoparticle Manufacturer.”
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer